Biontech Se Stock Today
| BNTX Stock | USD 110.97 6.01 5.14% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
BioNTech is trading at 110.97 as of the 25th of February 2025; that is 5.14 percent decrease since the beginning of the trading day. The stock's open price was 116.98. BioNTech has only four percent chance of going through some form of financial distress over the next 2 years, but has generated negative returns over the last 90 days. Note, on October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of BioNTech SE's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2019 | Category Healthcare | Classification Health Care |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 239.74 M outstanding shares of which 2.74 M shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. More on BioNTech SE
Moving together with BioNTech Stock
Moving against BioNTech Stock
BioNTech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO CoFounder | Ugur MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, Biotech, Computers, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioNTech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioNTech's financial leverage. It provides some insight into what part of BioNTech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioNTech SE (BNTX) is traded on NASDAQ Exchange in USA. It is located in An der Goldgrube 12, Mainz, Germany, 55131 and employs 6,133 people. BioNTech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 28.04 B. BioNTech SE conducts business under Biotechnology sector and is part of Health Care industry. The entity has 239.74 M outstanding shares of which 2.74 M shares are currently shorted by private and institutional investors with about 3.76 trading days to cover.
BioNTech SE currently holds about 9.33 B in cash with 5.37 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.3.
Check BioNTech Probability Of Bankruptcy
Ownership AllocationBioNTech holds a total of 239.74 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.18 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. On October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of BioNTech SE's common stock.
Check BioNTech Ownership Details
BioNTech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Altrinsic Global Advisors Llc | 2024-12-31 | 627.5 K | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 614.3 K | |
| Ubs Group Ag | 2024-12-31 | 529.1 K | |
| Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main | 2024-12-31 | 501.9 K | |
| Dekabank Deutsche Girozentrale | 2024-12-31 | 481.4 K | |
| Fred Alger Management, Llc | 2024-12-31 | 465.4 K | |
| Abrdn Plc | 2024-12-31 | 385.7 K | |
| Squarepoint Ops Llc | 2024-12-31 | 369.6 K | |
| Quinn Opportunity Partners Llc | 2024-12-31 | 356.2 K | |
| Baillie Gifford & Co Limited. | 2024-12-31 | 8.2 M | |
| Fmr Inc | 2024-12-31 | 7.7 M |
BioNTech Historical Income Statement
BioNTech Stock Against Markets
BioNTech Corporate Management
| Katalin Kariko | Senior Therapies | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Annemarie Hanekamp | Chief Board | Profile | |
| Sylke Maas | Vice Strategy | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Siegbert Kloos | Datand Digital | Profile | |
| Beate Berns | Senior Resources | Profile |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.